Vaxcyte Completes Enrollment for All VAX-31 Phase 3 Trials, Reports Strong Q1 Cash Position

summarizeSummary

Vaxcyte announced the completion of enrollment for all VAX-31 adult Phase 3 and infant Phase 2 trials, alongside a strong cash position of $2.7 billion following a $601.8 million equity offering.

check_boxKey Events

• VAX-31 Phase 3 Adult Trials Fully Enrolled

  Enrollment is now complete for the OPUS-1, OPUS-2, and OPUS-3 Phase 3 trials evaluating VAX-31 for invasive pneumococcal disease and pneumonia in adults. Topline data for OPUS-1 is expected in Q4 2026, with OPUS-2 and OPUS-3 results in H1 2027.

• VAX-31 Infant Phase 2 Study Enrollment Completed

  The VAX-31 infant Phase 2 dose-finding study has completed enrollment, with topline data from the primary immunization series and booster dose expected by the end of H1 2027.

• Strong Cash Position Maintained

  Cash, cash equivalents, and investments totaled approximately $2.7 billion as of March 31, 2026, including $601.8 million in net proceeds from a February 2026 equity offering, providing a substantial runway for pipeline development.

• VAX-A1 Phase 1 Study Initiation Planned

  The company expects to initiate a Phase 1 adult clinical study for VAX-A1, a vaccine candidate to prevent disease caused by Group A Strep, in mid-2026.

auto_awesomeAnalysis

Vaxcyte, a clinical-stage vaccine company, announced significant progress in its lead VAX-31 vaccine program, completing enrollment for all three adult Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) and the infant Phase 2 study. These milestones are critical for advancing VAX-31 towards potential regulatory submission and commercialization. The company also reported a robust cash position of approximately $2.7 billion, bolstered by the successful completion of a $601.8 million net proceeds equity offering in February 2026. While the net loss widened due to increased R&D expenses, this reflects the accelerated development of its pipeline, including plans to initiate a Phase 1 study for VAX-A1 in mid-2026. The strong financial runway and consistent execution on clinical timelines de-risk the company's development path.